Pharmacoeconomics of voriconazole

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 877-887

  Rubio Terres, Carlos ^a   Grau, Santiago ^b  

^a Health Value ^*  (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Antifungal drugs; Invasive fungal infections; Pharmacoeconomics; Voriconazole

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; BIOEQUIVALENCE; CANDIDEMIA; CANDIDIASIS; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFECTION RISK; REVIEW; SURVIVAL;

ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ECONOMIC; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 77949886578     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003649555     Document Type: Review

References (76)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-647
2. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006;3:35-40
3. Scott LJ, Simpson D. Voriconazole. A review of its use in the management of invasive fungal infections. Drugs 2007;67:269-298
4. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020
5. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013-1025
6. Grau S. Coste-efectividad de voriconazol. Rev Esp Quimioter Mongr 2009;2:41-47
7. Wilson L, Reyes C, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34
8. Rentz AM, Halpern MT, Bowden R. The impact of candidaemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-788
9. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000;31:1524-1528
10. Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther 1998;20:40-57
11. Wingard JR, Herbrecht R, Mauskopf J, et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007;9:128-135
12. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693
13. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618
14. Ullman AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43(4):e29-38
15. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-818
16. Al-Mohsen I, Hughes WT. Systemic antifungal therapy: past, present and future. Ann Saudi Med 1998;18:28-38
17. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189
18. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-1186
19. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347
20. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359
21. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America. Clin Infect Dis 2009;48:503-535
22. Azanza JR, Urdaneta MM, Garćia E, et al. Voriconazol. Propiedades farmacocinéticas y farmacodinámicas, interacciones y monitorización terapéutica. Rev Esp Quimioter Mongr 2009;2:12-16
23. Shehab N, DePestel DD, Mackler ER, et al. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 2007;27:970-979
24. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360
25. Dixon S, McKeen E, Tabberer M, et al. Economic evaluations of treatments for systemic fungal infections. A systematic review of the literature. PharmacoEconomics 2004;22:421-433
26. Johnson MD, Kleinberg M, Danziger L, et al. Pharmacoeconomics of antifungal pharmacotherapy-challenges and future directions. Expert Opin Pharmacother 2005;6:2617-2632
27. Moeremans K, Annemans L. Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opin Pharmacother 2006;7:1931-1943
28. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidaemia on outcomes of critically ill patients. Am J Med 2002;113:480-485
29. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17:168-175
30. Olaechea PM, Palomar M, Leon-Gil C, et al. Economic impact of Candida colonization and Candida infection in the critically patient. Eur J Clin Microbiol Infect Dis 2004;23:323-330
31. Slavin M, Fastenau J, Sukarom I, et al. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004;8:111-120
32. Laupland KB, Gregson DB, Church DL, et al. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-537
33. Sheng WH, Wang JT, Lu DC, et al. Comparative impact of hospital-acquired infections on medical costs, length of hospital stay and outcome between community hospitals and medical centres. J Hosp Infect 2005;59:205-214
34. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidaemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645
35. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidaemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-1239
36. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidaemia: a case-control study using data from population-based candidaemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-547
37. Gagne JJ, Breitbart RE, Maio V, et al. Cost associated with candidaemia in a hospital setting. Pharm Ther 2006;31:586-619
38. Zaoutis TE, Heydon K, Chu J, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006;117:711-716
39. Craver CW, Blanchette CM, Gasper S. Costs and outcomes associated with fluconazole treatment failure for invasive Candida infection in hospitalized patients. Am J Health Sys Pharm 2006:P252E
40. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008;46:97-112
41. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407
42. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-2483
43. Hennen CR. Pharmacoeconomic evaluations of antifungal therapies. Curr Med Res Opin 2009;25:1751-1758
44. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415
45. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234
46. Calabró A, Follador W. Custo-efectividade de voriconazol versus anfotericina B no tratamiento da aspergilose invasiva. RBM Rev Bras Med 2003;60:528-535
47. Marbaix S, Marciniak A, De Mees V, et al. Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium. Value Health 2003;6:750
48. Soto J, Grau S, Mateu-de Antonio J. Eficiencia de voriconazol (V-FEND) en el tratamiento de la aspergilosis invasiva. Rev Esp Econ Salud 2003;2:358-362
49. Rotstein C, Cragin L, Laverdière M, et al.; the Canadian Expert Panel. Economic evaluation of voriconazole for the treatment of candidaemia in Canadian adults. Can J Infect Dis Med Microbiol 2008;19:219-226
50. Garbino J, Schnetzler G, Roberts C. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost-saving if "expensive" voriconazole is only used on demand? Swiss Med Wkly 2005;135:624-630
51. Grau S, Mateu-de Antonio J, Soto J, et al. Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva. Farm Hosp 2005;29:5-10
52. Jansen JP, Meis JF, Blijlevens NM, et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005;21:1535-1546
53. Lewis JS, Boucher HW, Lubowski TJ, et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy 2005;25:839-846
54. Mesrobian X, Loftus J, Roberts C, et al. Cost-effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK. Value Health 2005;8:A20
55. Wenzel R, Del Favero A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericon B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55:352-361
56. Aiello E, Dignati C, de Vedia L, et al. Costo-efectividad de voriconazol versus anfotericina B deoxicolato en el tratamiento inicial de aspergilosis invasiva. Rev Panam Infectol 2006;8:18-25
57. Jansen JP, Kern WV, Cornely OA, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9:12-23
58. Ravasio R, Pizzarelli G. Valutazione economica di voriconazolo versus amfotericina B convenzionale nel trattamento di prima linea delĺ aspergillosi nei pazienti immunocompromessi. PharmacoEconomics Ital Res Art 2006;8:45-54
59. Ament JHA, Hübben MWA, Verweij PE, et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 2007;60:385-393
60. Doḿinguez-Gil A, Mart́in I, Garćia M, et al. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Invest 2007;27:197-205
61. Greene RE, Mauskopf J, Roberts CG, et al. Comparative cost-effectiveness of voriconazole and amphotericin B in the treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007;64:2561-2568
62. Van Campenhout H, Marbaix S, Derde MP, et al. Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results. Clin Drug Investig 2008;28:509-521
63. Selleslag D, Vogelaers D, Marbaix S. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Acta Clin Belg 2009;64:393-398
64. Arnold T, Donegan S, Kleinberg M, et al. Cost-effectiveness of implementing an IV antifungal to oral voriconazole conversion in a cancer center. 42nd Annual Meeting of IDSA; Boston: 178-September 30-October 3, 2004
65. Collins CD, Stuntebeck ER, DePestel DD, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Invest 2007;27(4):233-241
66. Riedel A, Choe L, Inciardi J, et al. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis 2007;7:70-76
67. Shehab N, DePestel DD, Mackler ER, et al. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 2007;27:970-979
68. Roma-Sanchez E, Poveda-Andres JL, Garćia-Pellicer J, et al. Estudio coste-efectividad de la estrategia emṕirica antifungica en pacientes oncohematologicos. Farm Hosp 2008;32:7-17
69. Slobbe L, Polinder S, Doorduijn JK, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia- myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008;47:1507-1512
70. Al-Badriyeh D, Liew D, Stewart K, et al. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chem 2009;63:197-208
71. Rotstein C, Cragin L, Laverdiére M, et al. Economic evaluation of voriconazole for the treatment of candidaemia in Canadian adults. Can J Infect Dis Med Microbiol 2008;19:219-226
72. Sacristán JA, Oliva J, Del Llano J, et al. What is an efficient technology in Spain? Gac Sanit 2002;16:334-343
73. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 2008;26:733-744
74. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-379
75. Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2008. KCE reports 100C (D/2008/10.273/96)
76. International Society for Pharmacoeconomics and Outcomes Research. ISPOR Good Outcomes Research Practices & Issues Index. Available from: http://www.ispor.org/ workpaper/practices-index.asp [Last accessed January 2010]